Pd-1-gfp Transfection
Pd-1-gfp Transfection - Related Videos
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
0 Views •
2025
This protocol describes a blockade assay for PD-1/PD-L1 inhibitors using surface plasmon resonance technology. It employs a dual-step immobilization strategy and a tailored buffer system to accurately measure response units, facilitating the assessment of blockade rates for compounds or biologics. Additionally, it supports the high-throughput identification of PD-1/PD-L1 inhibitors.
07:13
Immunoprecipitation Assay to Study Enzyme Receptor Interactions in Transfected Cells
0 Views •
2025
In this video, we demonstrate a technique to perform the co-immunoprecipitation of GFP-tagged wild-type and mutated PD-1 proteins using beads coated with anti-GFP antibodies. The bead-bound PD-1-GFP proteins are incubated with SHP2 proteins that interact with PD-1, enabling the identification of specific structural motifs in PD-1 that play a critical role in SHP2 interaction.
07:28
Transfection, Selection, and Colony-picking of Human Induced Pluripotent Stem Cells TALEN-targeted with a GFP Gene into the AAVS1 Safe Harbor
0 Views •
Cited by 12 •
2015
TALEN-mediated gene editing at the safe harbor AAVS1 locus enables high-efficiency transgene addition in human iPSCs. This protocol describes the procedures for preparing iPSCs for TALEN and donor vector delivery, transfecting iPSCs, and selecting and isolating iPSC clones to achieve targeted integration of a GFP gene to generate reporter lines.
07:28
An Introduction to Transfection
0 Views •
2023
Transfection is the process of inserting genetic material, such as DNA and double stranded RNA, into mammalian cells. The insertion of DNA into a cell enables the expression, or production, of proteins using the cells own machinery, whereas insertion of RNA into a cell is used to down-regulate the production of a specific protein by stopping translation. While the site of action for transfected RNA is the cytoplasm, DNA must be transported to the nucleus for effective transfection. There, the...
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
0 Views •
Cited by 2 •
2024
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
FAQs
The fusion links PD-1 abundance to a visible fluorescent signal, while its spatial pattern provides information about receptor localization. Changes in where fluorescence appears can therefore be examined alongside overall signal intensity, helping distinguish altered receptor distribution from differences in the amount of expressed construct. This makes the approach useful for tracking receptor behavior inside cells.
Localization and trafficking show how the receptor is distributed and moved within the cell, rather than only whether it is present. In immunology experiments, these features can be compared during immune-cell activation or pathogen exposure. Such comparisons help connect cellular conditions with changes in PD-1 positioning and provide context for interpreting checkpoint-related regulation.
The fluorescent receptor can be examined in relation to PD-L1 or PD-L2, allowing investigators to study where these checkpoint components may be associated in the cellular system. This is relevant when activation or pathogen exposure changes receptor distribution or trafficking. These observations help clarify how checkpoint interactions are organized visually.
After DNA delivery, researchers can evaluate the expressed fusion through fluorescence microscopy or related assays. Microscopy supplies visual information about PD-1 distribution and localization, whereas related measurements can be used to assess the abundance of the fusion protein. Using these readouts together connects construct expression with receptor positioning in the host cell.
In immunology and infection research, the method is useful when investigators need to follow checkpoint-receptor behavior under relevant cellular conditions. Studies can compare PD-1 distribution, trafficking, or interactions with PD-L1 and PD-L2 during immune-cell activation or pathogen exposure. This supports analysis of how those contexts relate to immune regulation and receptor-centered responses.
Measurements from the fusion system can support T-cell exhaustion studies by examining PD-1-related patterns in relevant experimental contexts. They also provide a way to examine checkpoint-targeted interventions at the level of receptor distribution, trafficking, or interaction patterns. The value lies in linking visible receptor behavior with broader questions about immune regulation, rather than relying on expression alone.